Oral Administration of the Probiotic Strain Escherichia coli Nissle 1917 Reduces Susceptibility to Neuroinflammation and Repairs Experimental Autoimmune Encephalomyelitis-Induced Intestinal Barrier Dysfunction
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) with an increasing incidence in developed countries. Recent reports suggest that modulation of the gut microbiota might be one promising therapy for MS. Here, we investigated whether the probiotic Escherichia coli strain Nissle 1917 (ECN) could modulate the outcome of experimental autoimmune encephalomyelitis (EAE), a murine model of MS. We evidenced that daily oral treatment with ECN, but not with the archetypal K12 E. coli strain MG1655, reduced the severity of EAE induced by immunization with the MOG35-55 peptide. This beneficial effect was associated with a decreased secretion of IFN-g and an increased production of the anti-inflammatory cytokine IL-10 by autoreactive CD4 T cells, both in peripheral lymph nodes and CNS. Interestingly, ECN-treated mice exhibited increased numbers of MOG-specific CD4+ T cells in the periphery contrasting with severely reduced numbers in the CNS, suggesting that ECN might affect T cells migration from the periphery to the CNS through a modulation of their activation and/or differentiation. In addition, we demonstrated that EAE is associated with a profound defect in the intestinal barrier function and that treatment with ECN, but not with MG1655, repaired intestinal permeability dysfunction. Collectively, our data reveal that EAE induces a disruption of the intestinal homeostasis and that ECN protects from disease and restores the intestinal barrier function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead
Kostic, A. D., Xavier, R. J., & Gevers, D. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.009 · Cited by 1,789
Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis
Lee, Y. K., Menezes, J. S., Umesaki, Y., & Mazmanian, S. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000082107 · Cited by 1,323 · cited 1×
“Likewise, the mono-colonization of the gut of C57BL/6 mice with segmented-filamentous bacteria promoted Th17 accumulation in the spinal cord and restored EAE development (23).”
BackgroundAlterations of the human gut microbiome in multiple sclerosis
Jangi, S., Gandhi, R., Cox, L. M., Li, N., von Glehn, F., Yan, R., Patel, B., Mazzola, M. A., Liu, S., Glanz, B. L., et al. (2016) · Nature Communications · doi:10.1038/ncomms12015 · Cited by 1,307 · cited 3×
“Indeed, recent studies have demonstrated that RRMS patients exhibited alterations in their gut microbiota composition (19, 50) and that these dysbiotic microbial populations profoundly altered gene expression of monocytes and T cells, which are involved both in the initiation phase of immunity and…”
BackgroundKruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037747 · Cited by 1,285 · cited 1×
“Escherichia coli strain Nissle 1917 (Mutaflor ® , ECN) is a Gram-negative microorganism with probiotic properties that has been successfully used for the treatment of intestinal inflammation, especially in patients suffering from ulcerative colitis (26).”
BackgroundCommensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination
Berer, K., Mues, M., Koutrolos, M., Rasbi, Z. A., Boziki, M., Johner, C., Wekerle, H., & Krishnamoorthy, G. (2011) · Nature · doi:10.1038/nature10554 · Cited by 1,251
Chaudhry, A., Samstein, R. M., Treuting, P., Liang, Y., Pils, M. C., Heinrich, J.-M., Jack, R. S., Wunderlich, F. T., Brüning, J. C., Müller, W., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.03.018 · Cited by 980
Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls
Chen, J., Chia, N., Kalari, K. R., Yao, J. Z., Novotna, M., Paz Soldan, M. M., Luckey, D. H., Marietta, E. V., Jeraldo, P. R., Chen, X., et al. (2016) · Scientific Reports · doi:10.1038/srep28484 · Cited by 933 · cited 1×
“Indeed, recent studies have demonstrated that RRMS patients exhibited alterations in their gut microbiota composition (19, 50) and that these dysbiotic microbial populations profoundly altered gene expression of monocytes and T cells, which are involved both in the initiation phase of immunity and in the activation of…”
BackgroundA protective function for interleukin 17A in T cell–mediated intestinal inflammation
O'Connor Jr, W., Kamanaka, M., Booth, C. J., Town, T., Nakae, S., Iwakura, Y., Kolls, J. K., & Flavell, R. A. (2009) · Nature Immunology · doi:10.1038/ni.1736 · Cited by 756 · cited 1×
“Thus, our results suggest that the mechanism underlying the resistance to EAE of ECN-treated animals could results from a defective differentiation of autoreactive CD4+ T cell in the periphery, which is known to account for their egress from the periphery to the CNS (51, 52).”
ResultKhoury, S. J., Hancock, W. W., & Weiner, H. L. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.5.1355 · Cited by 708 · cited 1×
“In this regard, EAE recovery is associated with increased production of IL-10, which is known to suppress EAE (57, 58).”
Background
Cited by
Probiotic species in the modulation of gut microbiota: An overview
Azad, M. A. K., Sarker, M., Li, T., & Yin, J. (2018) · BioMed Research International · doi:10.1155/2018/9478630 · Cited by 803
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Gurbatri, C. R., Lia, I., Vincent, R., Coker, C., Castro, S., Treuting, P. M., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0876 · Cited by 647
A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders
Sorboni, S. G., Moghaddam, H. S., Jafarzadeh-Esfehani, R., & Soleimanpour, S. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00338-20 · Cited by 522
The intestinal barrier in disorders of the central nervous system
Pellegrini, C., Fornai, M., D'Antongiovanni, V., Antonioli, L., Bernardini, N., & Derkinderen, P. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00241-2 · Cited by 239
Probiotics in the dairy industry—Advances and opportunities
Gao, J., Li, X., Zhang, G., Sadiq, F. A., Simal‐Gandara, J., Xiao, J., & Sang, Y. (2021) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12755 · Cited by 195
Gut microbiota and probiotics: Novel immune system modulators in myasthenia gravis?
Rinaldi, E., Consonni, A., Guidesi, E., Elli, M., Mantegazza, R., & Baggi, F. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13567 · Cited by 57
Jiang, J., Chu, C., Wu, C., Wang, C., Zhang, C., Li, T., Zhai, Q., Yu, L., Tian, F., & Chen, W. (2021) · Food & Function · doi:10.1039/d0fo03203d · Cited by 52
Gut microbiota in multiple sclerosis and animal models
Schumacher, S. M., Doyle, W. J., Hill, K., & Ochoa‐Repáraz, J. (2025) · The FEBS Journal · doi:10.1111/febs.17161 · Cited by 21
Parodi, B., Sanna, A., Cedola, A., Uccelli, A., & Kerlero de Rosbo, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655212 · Cited by 20
“Furthermore, in EAE, improvement of the intestinal barrier function through treatment with a probiotic leads to a decreased infiltration of the CNS by inflammatory T cells, resulting in less severe disease (65).”
Background
Metadata
- Authors
- Secher, T., Kassem, S., Benamar, M., Bernard, I., Boury, M., Barreau, F., Oswald, E., & Saoudi, A.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2017-09-14
- Volume
- 8
- Pages
- 1096-1096
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2755772264
- Cited by
- 148
- References
- 17
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.